Understanding Anemia in a 55-Year-Old Female with Vaginal Bleeding

QUESTION

8.9o F/37.2o C 99.0o F/37.2o C Heart Rate (BPM) 120 126 Blood Pressure (mmHg) 90/48 84/44 Oxygen Saturation (SpO2) 92% 92% Laboratory Test Result (0920) Reference Range Hematocrit (HCT) 32% 42%-52% (0.42-0.52 volume fraction) Hemoglobin (HGB) 8.0 g/dL 14-18 g/dL (140-180g/L) Platelets 150,000 mm3 150,000-400,000/mm3 (150-400 × 109/L) Iron 55 mcg/dL 60-160 mcg/dL (11-29 μmol/L) A 55-year-old female client presents to urgent care. She has been experiencing large amounts of vaginal bleeding with clots in the last 2 weeks, fatigue, weakness, dizziness when changing position, and increased heart rate. The client denies pain. She has been having symptoms of hot flashes and night sweats for a year. She was prescribed the estradiol patch for hormone replacement therapy. Surgical history includes a tonsillectomy at age 8, a fractured left arm at age 10, and two Caesarean childbirths. The nurse monitors the client’s vital signs and reviews the lab results and the provider notes. Provider Notes 0945: Review of home medication of estradiol patch noted. Both estrogen and progesterone replacement therapy should have been prescribed since client still has an intact uterus. Review of lab work of decreased HGB, HCT, and iron levels indicates anemia from blood loss due to vaginal bleeding

ANSWER

Understanding Anemia in a 55-Year-Old Female with Vaginal Bleeding

Introduction

In this medical case, we delve into the presentation of a 55-year-old female client who sought urgent care due to alarming symptoms, including heavy vaginal bleeding with clots, fatigue, weakness, dizziness upon position changes, and an increased heart rate. The client also reported experiencing hot flashes and night sweats for the past year, for which she had been prescribed an estradiol patch for hormone replacement therapy. This essay aims to discuss the client’s condition, focusing on the interpretation of her vital signs and laboratory test results, as well as the significance of hormone replacement therapy.

Clinical Presentation

The client’s symptoms, notably heavy vaginal bleeding, fatigue, and dizziness, are indicative of a concerning underlying issue. Although she denies pain, her presentation suggests a potential serious health concern. Additionally, her report of hot flashes and night sweats is suggestive of menopausal symptoms.

Vital Signs

The client’s vital signs provide valuable information for the healthcare provider. Her temperature of 99.0°F (37.2°C) falls within the normal range, indicating the absence of fever. However, her heart rate of 126 beats per minute (BPM) is elevated, which is consistent with her reported symptoms of increased heart rate. This tachycardia could be attributed to anemia or other underlying causes.

Blood Pressure

The client’s blood pressure readings of 90/48 mmHg and 84/44 mmHg are lower than the typical range. Hypotension (low blood pressure) can be associated with anemia, which could explain her feelings of weakness and dizziness when changing position.

Oxygen Saturation

Her oxygen saturation (SpO2) level of 92% indicates that her blood is adequately oxygenated. However, it is important to monitor this closely, as anemia can potentially impact oxygen-carrying capacity.

Laboratory Test Results

The laboratory test results are particularly revealing. The decreased levels of hemoglobin (HGB) and hematocrit (HCT) at 8.0 g/dL and 32%, respectively, are below the normal ranges of 14-18 g/dL and 42%-52%. These findings suggest that the client is suffering from anemia. Anemia can be caused by various factors, but in this case, the provider’s notes highlight the likely cause: blood loss due to vaginal bleeding.

Furthermore, the iron levels, which are at 55 mcg/dL, are also lower than the normal range of 60-160 mcg/dL. This supports the hypothesis of anemia due to chronic blood loss.

Hormone Replacement Therapy

The provider’s notes are instrumental in understanding the client’s hormone replacement therapy. The client had been prescribed an estradiol patch, which contains estrogen, for her menopausal symptoms. However, it is important to note that in women with an intact uterus, both estrogen and progesterone replacement therapy should be prescribed to prevent endometrial hyperplasia and the risk of uterine cancer. This oversight is crucial to address, as hormone replacement therapy plays a pivotal role in symptom management during menopause.

Conclusion

In summary, the 55-year-old female client’s presentation with heavy vaginal bleeding, anemia, and associated symptoms necessitates thorough evaluation and intervention. The elevated heart rate, low blood pressure, and decreased hemoglobin and hematocrit levels are indicative of anemia secondary to chronic blood loss. Furthermore, the hormone replacement therapy prescribed for menopausal symptoms needs to be revised to include both estrogen and progesterone for safety and efficacy. The healthcare provider should promptly address these concerns to ensure proper management and improve the client’s overall well-being.